ArticleFrontiers in oncology2025
Exploring the mechanism of action of succinic acid in ovarian cancer via single-cell sequencing of the tumor immune microenvironment.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TCA cycle-derived oncometabolites in cancer and the immune microenvironment.Journal of biomedical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The main treatments for ovarian cancer are surgery, chemotherapy, radiotherapy, and targeted therapy. Targeted therapy is a new treatment method that has emerged in recent years and relies on specific molecular targets to treat cancer. Succinic acid is a key intermediate product in the tricarboxylic acid cycle. Research has shown that succinic acid has antioxidant properties and can alleviate oxidative stress in cells and tissues. These findings indicate the potential application of succinic acid in antioxidant therapy and the prevention of oxidative damage. This study explored the potential targets and therapeutic mechanisms of succinic acid in ovarian cancer. Methods: Using bioinformatics and single-cell sequencing technology, the hub genes related to succinic acid and ovarian cancer and the frequency and gene expression patterns of different cell types in ovarian cancer patients and normal individuals were analyzed. Results: The frequency of immune cells, including B cells, CD4 Conclusions: This study investigated the potential therapeutic targets and mechanisms of succinic acid in ovarian cancer and the differences in immune cell infiltration and gene expression patterns, providing important insights for future tumor immunotherapy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.